We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Rakhi Naik

Rakhi Naik MD, MHS

Associate Director for Hematology, Hematology/Oncology Fellowship Program, Assistant Professor of Medicine, Hematology, Johns Hopkins Medicine, Baltimore, Maryland

Dr. Naik graduated from Duke University with a degree in Biomedical and Electrical Engineering and received her MD from Cornell Medical School. She also holds a Masters in Health Sciences (MHS) from the Johns Hopkins Bloomberg School of Public Health.  Dr. Naik has been at Hopkins since 2006, serving as Osler residency housestaff, hematology fellow, and Assistant Chief of Service (Chief Resident) prior to being recruited to faculty as an Assistant Professor in May 2013.  She currently serves as the Associate Director for Hematology for the Hematology-Oncology Fellowship Program. 

Dr. Naik’s primary research involves the genetic epidemiology of sickle hemoglobin disorders, with the goal of informing genetic counseling, screening and treatment guidelines. She is currently involved in several large-scale epidemiologic efforts using National Heart, Lung, and Blood Institute (NHLBI) population study cohorts to define clinical complications of sickle cell trait, including venous thromboembolism, renal disease, cardiovascular disease, and stroke.  

Dr. Naik serves on the American Society of Hematology (ASH) Committee on Training and is a member of the ASH Recruitment and Retention Working Group, which aims to increase the recruitment of trainees into benign hematology.